{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T15:27:50Z","timestamp":1767022070091,"version":"3.48.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Changzhou Science and Technology Plan Project","award":["CJ20240082"],"award-info":[{"award-number":["CJ20240082"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04090-x","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:47:15Z","timestamp":1763538435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Relationship between the BRAF-V600E variant allele frequency and clinicopathological characteristics of papillary thyroid carcinoma and its clinical application"],"prefix":"10.1007","volume":"16","author":[{"given":"Shijia","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenze","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guojun","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"1","key":"4090_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"4090_CR2","first-page":"443","volume":"70","author":"KD Miller","year":"2020","unstructured":"Miller KD, et al. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 2020;70(6):443\u201359.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4090_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4090_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"E Nichols","year":"2014","unstructured":"Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, Abdoli A, Abualhasan A, Abu-Gharbieh E, Akram TT, Al Hamad H. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676\u201390.","journal-title":"Cell."},{"issue":"12","key":"4090_CR5","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1210\/jc.2005-0987","volume":"90","author":"M Xing","year":"2005","unstructured":"Xing M, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"4090_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/0003134820919734","author":"M Yang","year":"2023","unstructured":"Yang M, et al. Correlation analysis of BRAF V600E mutation with clinical pathological features and prognosis of differentiated thyroid cancer patients with different risk stratification. Chin J Nuclear Med Mol Imaging. 2023:533\u20137. https:\/\/doi.org\/10.1177\/0003134820919734.","journal-title":"Chin J Nuclear Med Mol Imaging"},{"key":"4090_CR7","unstructured":"Chinese Society of Endocrinology, T., C.A.-C.A. Metabolism Surgery Group of the Chinese Society of Surgery, Chinese Association of Head, and C.S.o.N.M. Neck Oncology, China Anti-Cancer Association, Guidelines for the diagnosis and management of thyroid nodules and differentiated thyroid cancer. Chin J Endocrinol Metab. 2023. 39(03): pp. 181\u2013226."},{"issue":"6","key":"4090_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.annonc.2023.02.016","volume":"34","author":"J Ros","year":"2023","unstructured":"Ros J, et al. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol. 2023;34(6):543\u201352.","journal-title":"Ann Oncol"},{"issue":"2","key":"4090_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12022-011-9184-5","volume":"23","author":"A Chakraborty","year":"2012","unstructured":"Chakraborty A, et al. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol. 2012;23(2):83\u201393.","journal-title":"Endocr Pathol"},{"issue":"10","key":"4090_CR10","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1210\/en.2019-00315","volume":"160","author":"T Trybek","year":"2019","unstructured":"Trybek T, et al. Impact of BRAF V600E and TERT promoter mutations on response to therapy in papillary thyroid cancer. Endocrinology. 2019;160(10):2328\u201338.","journal-title":"Endocrinology"},{"issue":"4","key":"4090_CR11","first-page":"288","volume":"48","author":"J Wang","year":"2019","unstructured":"Wang J, et al. The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma. Zhonghua Bing Li Xue Za zhi\u2009=\u2009Chinese. J Pathol. 2019;48(4):288\u201392.","journal-title":"J Pathol"},{"issue":"7","key":"4090_CR12","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1530\/EC-19-0246","volume":"8","author":"C Yan","year":"2019","unstructured":"Yan C, et al. Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma. Endocr Connect. 2019;8(7):988\u201396.","journal-title":"Endocr Connect"},{"issue":"7","key":"4090_CR13","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/cncr.26500","volume":"118","author":"TH Kim","year":"2012","unstructured":"Kim TH, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012;118(7):1764\u201373.","journal-title":"Cancer"},{"issue":"6","key":"4090_CR14","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/cen.12386","volume":"80","author":"A Walczyk","year":"2014","unstructured":"Walczyk A, et al. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome? Clin Endocrinol (Oxf). 2014;80(6):899\u2013904.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"4090_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.23500","volume":"6","author":"G Fu","year":"2023","unstructured":"Fu G, et al. Facilitation of definitive cancer diagnosis with quantitative molecular assays of BRAF V600E and TERT promoter variants in patients with thyroid nodules. JAMA Netw Open. 2023;6(7):e2323500.","journal-title":"JAMA Netw Open"},{"issue":"13","key":"4090_CR16","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2017.2719","volume":"317","author":"H Lim","year":"2017","unstructured":"Lim H, et al. Trends in thyroid cancer incidence and mortality in the united States, 1974\u20132013. JAMA. 2017;317(13):1338\u201348.","journal-title":"JAMA"},{"issue":"1","key":"4090_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1\u2013133.","journal-title":"Thyroid"},{"key":"4090_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-1-0716-2505-7_5","volume":"2534","author":"CY Lo","year":"2022","unstructured":"Lo CY. Lymph node dissection for papillary thyroid carcinoma. Methods Mol Biol. 2022;2534:57\u201378.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"4090_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/jso.21234","volume":"99","author":"L Rotstein","year":"2009","unstructured":"Rotstein L. The role of lymphadenectomy in the management of papillary carcinoma of the thyroid. J Surg Oncol. 2009;99(4):186\u20138.","journal-title":"J Surg Oncol"},{"issue":"9\u201312","key":"4090_CR20","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1080\/00016489.2022.2115551","volume":"142","author":"M Rehell","year":"2022","unstructured":"Rehell M, et al. Complications in lymph node excision in the head and neck area. Acta Otolaryngol. 2022;142(9\u201312):738\u201342.","journal-title":"Acta Otolaryngol"},{"issue":"39","key":"4090_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008162","volume":"96","author":"A Su","year":"2017","unstructured":"Su A, et al. Risk factors of hypoparathyroidism following total thyroidectomy with central lymph node dissection. Medicine (Baltimore). 2017;96(39):e8162.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"4090_CR22","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-15-0628","volume":"173","author":"J Bollerslev","year":"2015","unstructured":"Bollerslev J, et al. European society of endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015;173(2):G1\u201320.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"4090_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.23500","volume":"6","author":"G Fu","year":"2023","unstructured":"Fu G, Chazen RS, Monteiro E, et al. Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules. JAMA Netw Open 2023; 6: e2323500.","journal-title":"JAMA Network Open."},{"key":"4090_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21031102","author":"S Lee","year":"2020","unstructured":"Lee S, Rauch J, Kolch W. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21031102.","journal-title":"Int J Mol Sci"},{"key":"4090_CR25","doi-asserted-by":"publisher","first-page":"106398","DOI":"10.1016\/j.phrs.2022.106398","volume":"184","author":"J Anjum","year":"2022","unstructured":"Anjum J, Mitra S, Das R, et al. A renewed concept on the MAPK. Signaling pathway in cancers: polyphenols as a choice of therapeutics. Pharmacol Res. 2022;184:106398.","journal-title":"Pharmacol Res"},{"key":"4090_CR26","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1210\/jc.2007-2825","volume":"93","author":"R Leboeuf","year":"2008","unstructured":"Leboeuf R, Baumgartner JE, Benezra M, et al. BRAFV600E mutation. Is associated with Preferential sensitivity to mitogen-activated protein kinase kinase Inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab. 2008;93:2194\u2013201.","journal-title":"J Clin Endocrinol Metab"},{"key":"4090_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fendo.2020.00102","volume":"11","author":"A Prete","year":"2020","unstructured":"Prete A, Borges De Souza P, Censi S, Muzza M, Nucci N. Sponziello. M. Update on fundamental mechanisms of thyroid cancer. Front Endocrinol. 2020;11:102.","journal-title":"Front Endocrinol"},{"key":"4090_CR28","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1158\/0008-5472.CAN-18-0365","volume":"78","author":"TB Shabaneh","year":"2018","unstructured":"Shabaneh TB, Molodtsov AK, Steinberg SM, et al. Oncogenic. BRAF(V600E) governs regulatory T-cell recruitment during melanoma tumorigenesis. Cancer Res. 2018;78:5038\u201349.","journal-title":"Cancer Res"},{"key":"4090_CR29","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41467-022-29000-5","volume":"13","author":"P Zhang","year":"2022","unstructured":"Zhang P, Guan H, Yuan S, et al. Targeting myeloid derived suppressor. Cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors. Nat Commun. 2022;13:1588.","journal-title":"Nat Commun"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04090-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04090-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04090-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T15:23:29Z","timestamp":1767021809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04090-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4090"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04090-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Third Affiliated Hospital of Nanjing Medical University (Approval No. [2024]KY013-01), in line with the principles of the Declaration of Helsinki. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2237"}}